Аспирин при антифосфолипидном синдроме

1. <div><p>Hughes G.R.V. Trombosis, abortion, cerebral disease and lupus anticoagulant. BMJ, 1983, 187, 1088-1089</p><p>Насонов Е.Л. Антифосфолипидный синдром. М., "Литгер- ра”, 2004, 13-22, 341-343.</p><p>Asherson R.A., Baguley Е., Hughes G.R.V. Antiphospholipid syndrom: five years follow-up. Ann. Rheum. Dis., 1991, 50, 805810</p><p>Wbod A. Drug therapy. N. Engl. J. Med., 1994, 330, 1287-1293</p><p>Панченко Е.П., Добровольский А.Б. Тромбозы в кардиологии. Механимы развития и возможности терапии. М., “Спорт и культура”, 1999, 277-278</p><p>Nfciss H.J., Aledort L.M. Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet, 1967, II, 495-497</p><p>VSmeJ.R. lnhibitionofprostaglandinsynthesisasamechanismof action of aspirin-like drugs. Nature (New Biol.), 1971, 231, 232235</p><p>Smith J.H., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol.), 1971, 231, 235-237</p><p>Насонов Е.Л. Кардиоваскулярные эффекты нестероидных противовоспалительных препаратов. Научно-практич. рев- матол., 2003, 3, 28-31.</p><p>Crofford L.J., Lipsky Р.Е., Brooks P. et al. Basic biology and clinical application of specific cyclogenase-2 inhibitors. Arthr. Rheum., 2000, 43, 3157-3160.</p><p>Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclogenase-2. N. Engl. J. Med., 2001, 345, 433-442.</p><p>Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am. J. Physiol., 1992,263, F18I-FI91.</p><p>Насонов Е.Л., Цветкова E.C., Тов HJI. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер.архив, 1998, 5, 8-14</p><p>Кукес В.Г., Остроумова О.Д. "Кардномагнил". Пособие для врачей, М., Никомед Россия-СНГ, 3-4.</p><p>Awtry Е.Н., LoscalzoJ. Aspirin. Circulat., 2000, 101, 1206-1215.</p><p>Patrono С., Coller В., Dalen J. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001, 119, 39S-63S.</p><p>Speir E., Yu Z.-X., Ferrans V.J. et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cycIooxygenase-2 in coronary artery smooth muscle cells. Circ. Res., 1998,83,210-216.</p><p>Wfeyand C.M., Kaiser М., Yang H. et al. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthr. Rheum., 2002,46, 457-466.</p><p>Carreras L.D., Machin S.J., Deman R. et al. Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacycline formation. Lancet, 1981, 1,244-246.</p><p>Schorer A.E., Wickham N.W. R., Watson K.V. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prosta cyclin release and platelet aggregation. Brit. J. Haemat., 1989,71,399-407.</p><p>Lellouche F. Martinuzzo М., Said P. et al. Imbalance of thromboxane/prostacyclin biosyntesis in patients with lupus anticoagulant. Blood, 1991, 78, 2894-2899.</p><p>Forastiero R., Martinuzzo М., Carreras L.O. et al. Anti-(52-gly- coprotein I antibodies: association with increased urinary excretion of platelet-derived thromboxane urinary metabolites. Thromb. Haemost., 1998, 79, 42-45.</p><p>Ferro D., Basili S., Roccaforte S. et al., Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. Arthr. Rheum., 1999, 42, 2689-2697.</p><p>Алекбсрова 3.C., Решетняк T.M., Насонов ЕЛ. и соавт, Уровни тромбоксана и про-стациклина у больных системной красной волчанкой с антифосфолипидным синдромом. Клинич. мед., 1994, 31-35.</p><p>Alarcon-Segovia D., Boffa М.С., Branch W. et al. Prophylaxis of the antiphopholipid syndrome: a consensus report. Lupus, 2003, 12,499-503.</p><p>Erkan D., Merrill J.T., Yazici Y. et al. High thrombosis rate after fetal loss in APS: effective prophylaxis with aspirin. Arthr. Rheum., 2001, 44, 1466-1467.</p><p>Erkan D,, Yazici Y., Peterson M.G. et al. A cross-sectional stady of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatol., 2002,41. 924-929.</p><p>Erkan D., Lockshin M.D. How much warfarin is enough in APS related thrombosis? Thromb. Research, 2004, 114, 435-442.</p><p>Derksen R.H., de Groot P.G., Kater L. et al. Patients with antiphospholipid antibodies and venous thromboembolism should receive long-term anticoagulant treatment. Ann. Rheum. Dis., 1993, 52, 689-692.</p><p>Khamashta M.A., Cuadrado M.J., Mujic F. et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med., 1995, 332, 993-997.</p><p>Antithrombotic Trialists' Collaboration. Collaborative meta- analisis of randomized trials of antiplatelct therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324,71-86.</p><p>Jeddy A.S., Gleason B.L. Aspirin and warfarin versus aspirin monotherapy after myocardial infarction. Ann. Pharmacother., 2003, 37, 1502-1505.</p><p>Mohr J.P., Thompson J.L.P., Lazar R.M. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischaemic stroke. N. Engl. J. Med., 2001, 345, 1444-1451.</p><p>Zibaeenezhad M.J., Mowla A., Sotbi M.H. Warfarin and aspirin versus aspirin alone in patients with acute myocardial infarction: a pilot study. Angiology, 2004, 55, 17-20.</p><p>Cervera R., Piette J.-C., Font J. et al. Antiphospholipid Syndrome clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthr. Rheum., 2002,46, 1019-1027.</p><p>Brey R.L., Chapman J., Levine S.R. et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus, 2003, 12,508-513.</p><p>Brey R.L., Levine S.R. APL and the brain: treatment (abstr.). Lupus, 2002, 559.</p><p>Levine S.R., Brey R.L., Tilley B.C. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 2004, 291, 576-584.</p><p>Brey R.L. Management of the neurological manifestations of APS - what do the trials tell us? Thromb. Research, 2004, 114, 489-499.</p><p>Gatenby P.A., Controversies in the antiphospholipid syndrome and stroke. Thromb. Research, 2004, 114, 483-488.</p><p>Derksen R.H.W.M., de Groot P.G., Kappell L.J. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology, 2003, 61, 111-114.</p><p>Ruiz-Ieastorza G., Khamashta K.A., Hunt B.J. et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: an analisis of a series of 66 patients treted with oral anticoagulation to a tagert international normalized ratio of 3,5. Arch. Intern. Med., 2002, 162, 1164-1169.</p><p>Lockshin М., Tenedios F„ Petri M. et al. Cardiac disease in the antiphospholipid syndrome recommendations for treatment. Committee consensus report. Lupus, 2003, 12, 518-523.</p><p>РешетнякТ.М., Мач Э.С., Александрова E.H. и соавт. Тром- боАСС в профилактике сосудистых нарушений при анти- фосфолипидном синдроме. Клинич. мед., 1999, 10, 30-35.</p><p>Alarcon-Segovia D., Sahchez-Guerrero.J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J. Rheumatol., 1989, 16, 1359.</p><p>Derksen R.H.W.M., de Groot P.G., Nieuwenhuis H.K. et al. How to treat women with antiphospholipid antibodies in pregnancy. Ann. Reum. Dis., 2001, 60, 1-3.</p><p>Derksen R.H.W.M., Khamashta M.A., Branch D.W. Management of the obstetric antiphospholipid syndrom. Arthr. Rheum., 2004, 50. 1028-1039.</p><p>Rai R„ Cohen H., Dave M. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. Br. Med.J., 1997,314, 253-257.</p><p>Khamashta M.A. Hughes Syndrome: antiphospholipid syndrom. Springer-ferlag, London, 2000, 391-396.</p><p>Wahl D.G., Bounameaux H., de Moerloose Ph. et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies. A decision analysis. Arch. Intern. Med., 2000, 160, 20422048.</p><p>Wajed J., Ahmad Y., Durrington P. N. et al. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatol., 2004, 43, 712.</p><p>Сидоренко Б.А., Преображенский Д.В. Клиническое применение антитромботических препаратов. М., ТОО ЛИА "Эвтаназия", 1998, 23-37.</p><p>Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000). Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet, 355, 1295-1302.</p><p>КаратеепА.Е. НПВП-индуцированные гастропатии. Методические рекомендации для врачей ревматологов, гастроэнтерологов, терапевтов. М., 2003, 5.</p><p>Wteil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ, 1995, 310, 827-830.</p><p>Caspi D., Lubart E., Graff E. et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthr. Rheum., 2000, 43. 103-108.</p><p>Fored C.M., Ejerblad E., Lindblad P. et al. Acetaminophen, aspirin, and chronic renal failure. N. Engl. J. Med., 2001, 345, 1801-1808.</p><p>Perncger T.V., Whelton P.K., Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1994, 331, 1675-1679.</p><p>Segal R., Lubart E., Leibovitz A. et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am. J. Med., 2003, 115, 462-466.</p><p>Curhan G.C., Knight E.L., Rosner B. et al. Lifetime nonnarcotic analgetic use and decline in renal function in women. Arch. Intern. Med., 2004, 164, 1519-1524.</p><p>Harmankaya O., Basturk Т., Ozturk Y. et al. Effect of acetylsali- cylic acid and dipiridamole in primary membranoproliferaiive glomerulonephritis tipe I. Int. Urol. Nephrol., 2001, 33, 583587.</p><p>He J., Whelton P.K., Vu B., et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998, 280, 1930-1935.</p><p>Pass S.E., Simpson R.W. Discontinuation and reinstitution of medications during the perioperative period. Am. J. Health-Syst. Pharm., 2004, 61,899-912.</p><p>Howard P.A. Aspirin resistance. Ann. Pharmacother., 2002, 36, 1620-1624.</p><p>Chamorro A., Escolar G., Revilla M. et al. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. J. Neurol. Sci.t 1999, 171, 110-114.</p><p>Taylor D.W., Barnett H.J., Haynes R.B. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy (ACE) Trial Collaborators. Lancet, 1999, 353, 2179-2184.</p><p>Johnson E.S., Lanes S.F., Wfentworth C.E. et al. Ametaregression analysis of the dose response effect of aspirin in stroke. Arch. Intern. Med., 1999,159, 1248-1253.</p><p>Beiglund U., Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with instabile coronary artery disease. Eur. Heart J., 1991, 12,428-433.</p><p>Kawasaki Т., Ozek Y., lgawa Т., Kambabayashi J. Increased platelet sensivity to collagen in individuals resistant to low-dose aspirin. Stroke, 2000, 31, 591-595.</p><p>Tselepis A.D., Tsoukatos D., Droudes C. et al. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction. Eur. J. Clin. Invest., 1991,21,490-496.</p><p>Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med., 2001, 345, 1809-1817.</p><p>Cipollone F., Ciabattoni G., Patrignani P. et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation, 2000, 102, 1007-1013.</p><p>Eikelboom J.W., Hirsh J., Weitz J.I. et al. Aspirin resistance and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk of cardiovascular outcomes. Circulation, 2002,105, 1650-1655.</p><p>Hankey G.J., Eikelboom J.W. Aspirin resistance. BMJ, 2004, 328, 477-479</p></div><br />